Dehay, B., Bourdenx, M., Gorry, P., Przedborski, S., Vila, M., Hunot, S., Singleton, A., Olanow, C.W., Merchant, K.M., Bezard, E., Petsko, G.A. and Meissner, W.G. (2015) Targeting α-Synuclein for Treatment of Parkinson’s Disease: Mechanistic and Therapeutic Considerations. The Lancet Neurology, 14, 855-866. https://doi.org/10.1016/S1474-4422(15)00006-X

has been cited by the following article:

• TITLE: Effect of Alteration of Glutathione Content on Cell Viability in α-Synuclein-Transfected SH-SY5Y Cells

  AUTHORS: Ken-Ichi Tanaka, Kanako Sonoda, Masato Asanuma

  KEYWORDS: α-Synuclein, L-Buthionine-SR-Sulfoximine, N-Acetyl-L-Cysteine, Glutathione, SH-SY5Y Cells, Parkinson’s Disease

  JOURNAL NAME: Advances in Parkinson's Disease, Vol.6 No.3, August 23, 2017

  ABSTRACT: It is well known that α-synuclein (αS) plays an important role in the pathogenesis of Parkinson’s disease (PD). Moreover, oxidative stress is also thought to be an important factor in PD due to induction of dopaminergic neuronal cell death by free radicals and enhancement of αS fibrillation by oxidized stress. In the present study, to clarify the role of glutathione (GSH), an intracellular antioxidant, on the molecular mechanism of αS-induced cell injury, we examined the effects of L-buthionine-SR-sulfoximine (BSO), a GSH synthase inhibitor, with or without N-acetyl-L-cysteine (NAC), a source of GSH, on αS-induced cell injury in human neuroblastoma SH-SY5Y cells. Treatment with BSO significantly reduced the cell viability of both empty-vector- and αS-transfected SH-SY5Y cells in a dose-dependent manner (p